Lumira Ventures, a Vancouver, Toronto, Montreal and Boston-based healthcare venture capital firm, closed two funds, totalling $255m.
The closings include:
- Lumira Ventures IV, a US$220m fund with participation from family offices, foundations, funds-of-funds, pension plans, sovereign government funds and strategic corporate investors. Investors in the fund include: Kensington Capital Partners, Fonds de Solidarité FTQ, Northleaf Capital Partners, Caisse de dépôt et placement du Québec, the Business Development Bank of Canada, Teralys Capital, the Ontario Capital Growth Corporation, Royal Bank of Canada, Investissement Québec, Fondaction, Alexandria Venture Investments, Angelini Pharma, China Grand Pharmaceutical and Healthcare Holdings, Vancity, and Amana Global Partners; and
- a $35m strategic venture fund launched in partnership with and international pharmaceutical company.
The vehicles will enable the firm to found and build innovative healthcare companies in Canada and the U.S.
Led by Peter van der Velden, co-founder and Managing General Partner, and Gerry Brunk, co-founder and Managing Director, Lumira Ventures is a healthcare focused multi-stage investor building innovative companies in the biotechnology, medical device and digital health sectors. These companies leverage innovations in genomics, cell therapy, gene therapy, bioengineering, robotics and artificial intelligence to develop their products.
Since the beginning of 2020, Lumira Ventures has achieved eight realizations and its portfolio companies have received two landmark FDA product approvals and collectively completed over US$800 million in new financings and IPOs. Lumira currently manages a portfolio of over 30 private and public companies.